[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osteoarthitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osteoarthitis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,73,101,160,184,213,238],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100642608","phase-2-cbd-knee-osteoarthritis-study-100642608",false,"NCT07638189","CBD Knee Osteoarthritis Study","Pilot Study Using Topical Cannabidiol (CBD) to Manage Osteoarthritic Knee Pain","Inclusion Criteria:\n\n1. Knee OA (grade 2-3 as measured by the Kellgren-Lawrence Classification)\n2. OA knee pain on the Visual Analog Pain Scale \\> 4 in either knee\n3. Receiving treatment at one of the eight Campbell Clinic Orthopaedics locations\n\nExclusion Criteria:\n\n1. Other forms of arthritis such as psoriatic arthritis or rheumatoid arthritis due to different sources of inflammation in these conditions\n2. Allergies to CBD or Castor Oil\n3. Current opioid use\n4. BMI of over 40\n5. Those who cannot walk without an assistance device (e.g., walker)\n6. Those who are currently on knee injections (i.e. cortisol or hyaluronic acid gel) for knee pain\n7. Patients scheduled for a knee replacement in the next 3-6 months\n8. Active cannabis or CBD use\n9. Alcohol consumption \\> 21 alcoholic drinks each week\n10. Active pregnancy, nursing, or actively planning a pregnancy\n11. Active chronic liver or renal disease\n12. Active depression\u002Fsuicidality\n13. Medications that interact with CBD in the liver that cannot be discontinued 14. Discretion of the Multiple Principal Investigators for concerns regarding noncompliance with the study intervention.","ALL","21 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Osteoarthritis of the knee is a common cause of pain in the US. The currently available medicines for knee osteoarthritis sometimes are not effective at relieving the pain or have unacceptable side effects. Thus, alternate pain relieving treatments are needed.\n\nCBD, an active chemical from the hemp derived cannabis sativa plant, has received a lot of attention for its potential pain relieving properties, but there has been limited research to find out if topically applied CBD can decrease pain from knee osteoarthritis. CBD lacks the psychoactive effects seen with marijuana use, because it does not contain THC which is responsible for those effects in marijuana. It is legal to use CBD in the State of Tennessee (site of study).\n\nThe CBD Knee Study is sponsored by the University of Tennessee Health Science Center and is a collaborative effort between doctors at UT and Campbell Clinic. In the CBD Knee Study, the investigators are examining whether topically applied CBD dissolved in Castor Oil will relieve knee pain in persons with knee osteoarthritis.\n\nPersons who take part in the study would need to come for study visits, fill out questionnaires about their health and knee pain, and would be asked to use the topical study oil on their knees. Taking part in the CBD Knee Study is voluntary.",[26],"Osteoarthitis",[28,29,30],"Randomized Clinical Trial","Cannabidiol (CBD)","Knee Pain","NOT_YET_RECRUITING","2026-06-04",{"date":34,"type":35},"2026-06-10","ACTUAL",{"date":37,"type":20},"2026-07-01",{"date":39,"type":20},"2028-03-30",{"name":41,"class":42},"University of Tennessee","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100639313","effects-of-kinesiotaping-in-osteoarthritis-100639313","NCT07606157","Effects of Kinesiotaping in Osteoarthritis","Effects of Adding Kinesiotaping to Conventional Physiotherapy on Pain, Function, and Kinesiophobia in Knee Osteoarthritis: A Randomized Controlled Trial","Taping","Inclusion Criteria:\n\n* Diagnosis of unilateral grade 2 knee osteoarthritis,\n* Age between 40 and 65 years,\n* Ability to understand and comply with assessments and interventions,\n* Independent ambulation without assistive devices,\n* No participation in a physiotherapy program for knee-related complaints within the previous year\n\nExclusion Criteria:\n\n* History of lower extremity surgery or trauma,\n* Presence of neurological or orthopedic conditions affecting gait or physical function,\n* Allergic reaction to kinesiotape,\n* Inability to walk independently.",true,"40 Years","60 Years",{"count":56,"type":20},60,[58],"NA","Knee osteoarthritis will be recognized as a leading cause of pain and functional disability, and conventional physiotherapy will remain a cornerstone of its management. Kinesiotaping will be widely used as an adjunct intervention; however, its additional benefit beyond standard rehabilitation programs will remain unclear.\n\nThis study will aim to investigate the additional effects of kinesiotaping combined with a conventional physiotherapy and rehabilitation program on pain, functional status, and kinesiophobia in individuals with unilateral knee osteoarthritis.\n\nA total of 60 participants with unilateral knee osteoarthritis will be included in this randomized controlled trial and will be assigned to either a conventional physiotherapy (CP) group or a kinesiotaping (KT) group. Both groups will receive a 4-week (12 sessions) physiotherapy program including ultrasound, transcutaneous electrical nerve stimulation, patellofemoral mobilization, and exercise. Kinesiotaping will be applied every 3 days in the KT group. Outcome measures will include pain (VAS), kinesiophobia (TSK, FABQ), functional performance (30-s sit-to-stand, stair climb test), dynamic balance (functional reach), and WOMAC.",[26],[62,63],"osteoarthritis","physiotherapy","2026-05-20",{"date":66,"type":35},"2026-05-26",{"date":68,"type":20},"2026-06-20",{"date":70,"type":20},"2027-06-20",{"name":72,"class":42},"Nazli Cigercioglu",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":43},"100637221","effect-of-high-intensity-laser-therapy-on-femoral-cartilage-in-knee-osteoarthritis-100637221","NCT07584603","Effect of High-Intensity Laser Therapy on Femoral Cartilage in Knee Osteoarthritis","The Role of High-intensity Laser Therapy on Femoral Cartilage Thickness in Patients With Knee Osteoarthritis","HILT-KOA","Inclusion Criteria:\n\n* Male and female participants aged 40-60 years.\n* Diagnosed with knee osteoarthritis (Kellgren-Lawrence grade II or III).\n* Knee pain for at least 3 months.\n* Visual Analogue Scale (VAS) score ≥ 3.\n* Willing to provide written informed consent and comply with treatment and follow-up schedule.\n\nExclusion Criteria:\n\n* History of knee surgery or traumatic knee injury.\n* Inflammatory arthritis (e.g., gout, psoriatic arthritis).\n* History of cancer or psychiatric illness.\n* Cognitive disorders (e.g., Parkinson's disease, Alzheimer's disease).\n* Severe comorbidities limiting exercise (e.g., severe COPD, heart failure, cerebrovascular event).\n* Hip or ankle joint disability.\n* Intra-articular knee injection within the past 3 months.",{"count":82,"type":20},58,[58],"This clinical trial will evaluate the effects of High-Intensity Laser Therapy (HILT) on femoral cartilage thickness and other clinical outcomes in people with knee osteoarthritis. Participants aged 40 to 60 years with grade II or III knee osteoarthritis will be randomly assigned to receive either HILT plus conventional physiotherapy or conventional physiotherapy alone. Both groups will receive 12 treatment sessions on alternate days for 4 weeks. The study will assess changes in cartilage thickness using ultrasound, as well as improvements in pain, knee movement, muscle strength, and daily function. Findings from this research may help improve physiotherapy treatment strategies for patients with knee osteoarthritis.",[86,26],"Osteoarthritis (OA) of the Knee",[88,89,90,91,92],"High Intensity Laser Therapy","Knee Osteoarthritis","Femoral Cartilage Thickness","High Level Laser Therapy","Osteoarthritis","2026-05-07",{"date":95,"type":35},"2026-05-13",{"date":37,"type":20},{"date":98,"type":20},"2027-05-10",{"name":100,"class":42},"University of Lahore",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":109,"maxAge":4,"enrollmentInfo":110,"targetDuration":111,"studyType":112,"phases":4,"briefSummary":113,"conditions":114,"keywords":129,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":43},"100636568","cartiz-registry-cartilage-arthropathy-and-imaging-under-tirzepatide-in-zone-stratified-cohorts---a-four-institute-mexican-observational-registry-100636568","NCT07567378","CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry","Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts (CARTIZ): A Prospective Observational Multi-Institutional Registry of the VAT-Articular-Cardiac-Aging Axis in Adults Exposed to Tirzepatide in Mexico, With Quantitative Knee Cartilage T2 Mapping, Cardiac CT Epicardial Adipose Tissue Radiomic Phenotyping, HLA Stratification, Longitudinal Multi-Frequency Bioimpedance Body Composition, and a Prespecified Surgical Tissue Acquisition Subcohort","CARTIZ","Inclusion Criteria:\n\n* 1\\. Age ≥18 years at the time of informed consent. 2. Currently receiving tirzepatide under an independent clinical indication (type 2 diabetes, insulin resistance, obesity with or without associated metabolic disease, renal protection, metabolic hypertension, or associated off-label metabolic use) prescribed by the treating physician independently of the registry.\n\n  3\\. Presence of at least one objectively documented musculoskeletal manifestation - current or historical - defined as any of: (i) inflammatory arthralgia affecting one or more joints with clinical, imaging, or serological support; (ii) CASPAR-positive psoriatic arthritis; (iii) radiographically documented knee osteoarthritis; (iv) enthesitis on physical examination or ultrasound; (v) documented inflammatory arthropathy of the spine or peripheral joints with a specialist diagnosis.\n\n  4\\. For the retrospective-prospective component: availability of clinical documentation of articular state prior to tirzepatide initiation in the patient's medical record. Documentation may include physical examination notes, imaging, laboratory values, or specialist consultation notes.\n\n  5\\. Signed informed consent for registry enrolment, longitudinal serum biobanking, HLA typing at INCMNSZ, quantitative knee MRI with T2 mapping at Ci3M UAM-Iztapalapa at Week 0 and Week 52, non-contrast cardiac CT at INCar at Week 0 and Week 52, multi-frequency bioelectrical impedance analysis at Universidad La Salle México at six timepoints, and (where applicable) medical record review. Each attestation is consented modularly within a single document.\n\n  6\\. Clinical plan to continue tirzepatide for at least 52 weeks from registry Week 0, based on the treating physician's evaluation of current clinical indication. Discontinuation during follow-up is captured as an outcome variable and does not remove the patient from the registry.\n\n  7\\. Capacity to attend scheduled follow-up visits and to undergo bilateral knee MRI at Ci3M (without severe claustrophobia requiring sedation, without absolute contraindication to MRI - see Exclusion 6) and non-contrast cardiac CT at INCar (without uncontrolled arrhythmia precluding ECG-gated imaging of diagnostic quality).\n\nFor the Surgical Tissue Subcohort (Cohort 3) only - additional criteria applied at the time of subcohort enrolment:\n\n8s. Scheduled clinically indicated cardiac surgery at the Instituto Nacional de Cardiología Ignacio Chávez (coronary artery bypass grafting, valve replacement, or combined procedures) during registry follow-up.\n\n9s. Specific additional informed consent for intraoperative collection of epicardial adipose tissue fragments.\n\nExclusion Criteria:\n\n* 1\\. Initiation or modification of a biologic disease-modifying antirheumatic drug (biologic DMARD) or JAK inhibitor within the 12 weeks prior to Week 0, or clinically anticipated initiation or modification during the first 12 weeks of follow-up. Washout may permit re-screening.\n\n  2\\. Major joint surgery within the 3 months prior to Week 0, or planned major joint surgery within the 12 months following Week 0, involving any joint scheduled for evaluation in the registry.\n\n  3\\. Intra-articular corticosteroid or hyaluronic acid injection within the 6 weeks prior to baseline biospecimen collection in any joint. Patients beyond the 6-week washout are eligible.\n\n  4\\. Active malignancy, with the exception of adequately treated non-melanoma skin carcinoma. History of malignancy in remission ≥5 years is permitted at the discretion of the treating investigator.\n\n  5\\. Current pregnancy, lactation, or planned pregnancy within the 12-month observation period.\n\n  6\\. Absolute contraindication to MRI, including non-MRI-compatible cardiac pacemaker or implanted defibrillator, ferromagnetic intracranial vascular clips, non-documented non-MRI-compatible cochlear implants, or other contraindication per the local MRI safety protocol.\n\n  7\\. Systemic rheumatologic disease other than psoriatic arthritis or osteoarthritis requiring active immunomodulation, specifically: seropositive rheumatoid arthritis on biologic therapy, active systemic lupus erythematosus on immunomodulation, active vasculitis on immunosuppression, or other systemic disease whose treatment confounds the inflammatory axis the registry is designed to characterize.\n\n  8\\. Inability to provide informed consent (cognitive impairment, language barrier not resolvable with site interpreter, or other incapacity to understand the protocol), or anticipated inability to complete the 52-week follow-up.\n\nFor the Surgical Tissue Subcohort (Cohort 3) only - additional exclusions:\n\n9s. Prior major cardiac surgery resulting in extensive pericardial adhesions that preclude safe intraoperative EAT fragment collection, as assessed by the operating cardiac surgeon.\n\n10s. Emergency cardiac surgery precluding the specific informed consent process.","18 Years",{"count":19,"type":20},"52 Weeks","OBSERVATIONAL","CARTIZ is a prospective observational clinical registry of adults in Mexico receiving tirzepatide (a dual GLP-1\u002FGIP receptor agonist) under an independent clinical indication - typically type 2 diabetes, insulin resistance, obesity, renal protection, metabolic hypertension, or associated off-label metabolic use. The registry is entirely observational: CARTIZ does not initiate, modify, interrupt, or supply tirzepatide, and does not dictate dose, route, or duration. All pharmacological exposure decisions are made by the treating physician independently of study participation. The registry is operationalized through a four-institute architecture integrating three Mexican National Institutes of Health and one national imaging laboratory. Core 1 (Knee Cartilage Imaging, Ci3M UAM-Iztapalapa) performs bilateral 3T MRI with quantitative T2 mapping at Week 0 and Week 52. Core 2 (Cardiac Imaging, Instituto Nacional de Cardiología Ignacio Chávez) performs non-contrast cardiac computed tomography for radiomic phenotyping of epicardial adipose tissue at Week 0 and Week 52 under cardiovascular Co-Principal Investigator Dr. Erick Alexánderson Rosas. Core 3 (HLA Typing, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Transplant Department) performs Class I and Class II HLA typing by PCR-SSO Reverse Luminex. Core 4 (Body Composition, Universidad La Salle México) performs multi-frequency bioelectrical impedance analysis (seca mBCA) at six longitudinal timepoints capturing visceral adipose tissue trajectory, phase-angle trajectory, appendicular skeletal muscle mass, and hydration ratios at zero marginal cost. The registry enrolls n=30 patients across three clinical sites with identical protocol (IMSS Clínica Río Magdalena, INCMNSZ outpatient clinic, and a private practice site in Mexico City), generating 60 evaluable knees and 30 paired cardiac CT studies. The primary co-endpoints address a mechanistic question no other tirzepatide study is positioned to answer: whether the articular response to tirzepatide in inflammatory arthropathy precedes and mechanistically precedes weight loss, through formal mediation analysis of Week-4 ACR20 response via high-sensitivity C-reactive protein, SERPINB2, and dipeptidyl peptidase-4 activity, restricted to the Mechanistic Analysis Set of patients with tirzepatide exposure ≤16 weeks at Week 0 and delta-BMI \\\u003C1.0 kg\u002Fm² through Week 4. A prespecified Surgical Tissue Subcohort is declared at initial registration to establish public scientific priority on direct human epicardial adipose tissue transcriptomic characterization under dual GIP\u002FGLP-1 receptor agonism. Subcohort participants who undergo clinically indicated cardiac surgery at INCar during follow-up (coronary artery bypass grafting, valve replacement, or combined procedures) are invited to provide specific additional informed consent for collection of epicardial adipose tissue fragments routinely excised during operative access and otherwise discarded as surgical waste. Operational launch is contingent on separate INCar tissue-specific approvals and will proceed via PRS record amendment when ready",[115,26,116,117,118,119,120,121,122,123,124,125,126,127,128],"Psoriatic Arthritis","Knee","Diabetes (DM)","Type 2 Diabetes Mellitus (T2DM)","Obesity (Disorder)","Insulin Resistance Syndrome","Metabolic Syndrome","Heart Failure","Preserved Ejection Fraction","Coronary Artery Disease","Atrial Fibrillation (AF)","Non Alcholic Fatty Liver Disease","Sarcopenia","Pericardium",[130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151],"Tirzepatide","Dual GIP\u002FGLP-1 receptor agonist","Multi-nutrient-stimulated hormones","Psoriatic arthritis","Inflammatory arthropathy","ACR20","Cartilage T2 mapping","Quantitative knee MRI","Epicardial adipose tissue","Cardiac CT radiomics","Fat Attenuation Index","HLA typing","Visceral adipose tissue","Phase angle","seca mBCA","Bioelectrical impedance analysis","Mediation analysis","Weight-independent effect","Off-label exposure","Mexican registry","Epicardial adipose transcriptomics","Single-nucleus RNA sequencing",{"date":153,"type":35},"2026-05-12",{"date":155,"type":20},"2026-05",{"date":157,"type":20},"2029-05",{"name":159,"class":42},"JULIO GRANADOS MONTIEL",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":167,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":21,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":43},"100631283","prp-injection-into-the-sacroiliac-joint-after-ipsilateral-tha-effects-on-early-recovery-and-function-sij-tha-randomized-trial-100631283","NCT07498660","PRP Injection Into the Sacroiliac Joint After Ipsilateral THA: Effects on Early Recovery and Function (SIJ-THA Randomized Trial)","Effect of Platelet-Rich Plasma Injection Into the Sacroiliac Joint After Ipsilateral Total Hip Arthroplasty on Early Rehabilitation and Patient Function: A Randomized Trial (SIJ-THA Trial)","Inclusion Criteria:\n\n* primary osteoarthritis of the hip;\n* qualification for elective total hip arthroplasty (THA);\n* age ≥45 years;\n* written informed consent;\n* ability to understand Polish.\n\nExclusion Criteria:\n\n* prior surgical treatment of the hip or sacroiliac joint;\n* malignancy;\n* developmental dysplasia of the hip;\n* rheumatologic diseases (rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis);\n* neurological or psychiatric disorders;\n* allergy to local anesthetics.","45 Years",{"count":56,"type":20},[58],"The study is an interventional, randomized, open-label (non-blinded), placebo-controlled trial. Preoperatively, patients scheduled for primary total hip arthroplasty (THA) will undergo a clinical examination in the Orthopaedic Department. Clinical tests will be performed to confirm sacroiliac joint (SIJ) dysfunction on the operated side. In addition, low-dose computed tomography (CT) will be used to assess structural changes in the SIJ.\n\nAll patients will complete patient-reported outcome measures related to the hip joint, including the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and the Harris Hip Score (HHS), as well as SIJ-related assessments, including the Oswestry Disability Index (ODI). Pain intensity will be assessed using the Visual Analogue Scale (VAS).\n\nFollowing THA, patients will be randomly allocated into two groups during their hospital stay. In the intervention group, platelet-rich plasma (PRP) will be injected into the sacroiliac joint, whereas the control group will receive an injection of normal saline. All injections will be performed in the operating theatre.\n\nAt discharge, patients will be scheduled for follow-up visits at 2, 6, and 12 weeks postoperatively. At each follow-up, patient-reported outcomes will be collected, including WOMAC and HHS for hip function, ODI for SIJ-related disability, and VAS for pain assessment of both the hip and sacroiliac joint.",[26,172,173,174],"Sacro Iliac Joint Pain","Hip Arthroplasty, Total","Sacro-Iliac Spondylosis","2026-03-23",{"date":177,"type":35},"2026-03-27",{"date":179,"type":20},"2026-04-01",{"date":181,"type":20},"2028-03-31",{"name":183,"class":42},"Medical University of Warsaw",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":52,"sex":16,"minAge":109,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":203,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":43},"100629430","evaluation-of-musculoskeletal-aging-and-related-disorders-via-advanced-clinical-imaging-100629430","NCT07474571","Evaluation of Musculoskeletal Aging and Related Disorders Via Advanced Clinical Imaging","A Comprehensive Evaluation of Musculoskeletal Aging and Degenerative Pathologies Using Multi-modal Clinical Imaging and Quantitative Analysis.","Inclusion Criteria:\n\n* Age: Adults aged at least 18 years.\n* Gender: No gender restrictions; both male and female participants are eligible.\n* Imaging Data: Participants must have completed relevant clinical imaging scans of skeletal sites, including but not limited to X-ray, CT (plain scan), or MRI (plain scan).\n* Anatomical Integrity: The skeletal structure of the target area must be free from congenital or acquired deformities.\n* Absence of Implants: No internal fixation materials or orthopedic implants in the skeletal areas being assessed.\n\nExclusion Criteria:\n\n* Pathological History: Patients with a history of prior pathological fractures.\n* Malignancy: Patients seeking treatment or diagnosed with bone tumors or other systemic malignancies.\n* Medication History: Patients with a history of long-term steroid use, which may significantly affect bone density and joint structure.\n* Recent Treatment: Patients who have undergone radiotherapy or chemotherapy within the past six months.\n* Data Quality: Patients whose imaging data is of insufficient quality for AI analysis or lacks clear clinical diagnostic \"gold standard\" references (e.g., missing DXA results for osteoporosis staging).",{"count":192,"type":20},2000,"Study Overview This clinical research focuses on the development and validation of a multimodal artificial intelligence (AI) platform designed for the automated diagnosis and precise staging of two major musculoskeletal conditions: Osteoporosis (OP) and Osteoarthritis (OA). By integrating diverse clinical imaging data, the study aims to provide a more objective and standardized approach to assessing bone and joint degeneration.\n\nTechnological Core: Intelligent Staging\n\nTraditional diagnosis often relies on manual interpretation, which can lead to inter-observer variability. This study employs deep learning and multimodal imaging to:\n\nFor Osteoporosis: Automatically quantify bone mineral density and micro-architectural changes to determine the stage of bone loss and evaluate fracture risk.\n\nFor Osteoarthritis: Identify subtle radiological markers such as joint space narrowing and osteophyte formation to categorize the severity of joint degeneration according to international staging standards (e.g., Kellgren-Lawrence scale).\n\nWhy This Matters Early Intervention: By identifying early-stage changes in bone density and joint integrity, clinicians can implement preventive treatments before significant disability occurs.\n\nStandardized Care: The intelligent diagnostic model provides a \"digital second opinion,\" ensuring consistent staging across different healthcare settings.\n\nEfficiency: The automated workflow reduces the workload of radiologists while maintaining high diagnostic accuracy.\n\nEthical Compliance The study is conducted at Peking University People's Hospital under the supervision of the Institutional Review Board (Approval No. 2026PHB097-001). It strictly adheres to international ethical standards, including the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines, to ensure patient data privacy and safety.",[26,195],"Osteoporosis",[197,198,199,200,201,202],"artificial intelligence","osteoarthitis","diagnosis","machine learning","osteoporosis","clinical images","RECRUITING","2026-03-17",{"date":206,"type":35},"2026-03-19",{"date":208,"type":35},"2005-11-01",{"date":210,"type":20},"2026-12-31",{"name":212,"class":42},"Peking University People's Hospital",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":21,"phases":222,"briefSummary":223,"conditions":224,"keywords":227,"overallStatus":203,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":234,"leadSponsor":236,"locationsCount":43},"100620713","percutaneous-transcatheter-genicular-embolization-in-osteoarthritis-100620713","NCT07361198","Percutaneous Transcatheter Genicular Embolization in Osteoarthritis","Inclusion Criteria:\n\n* Adults aged 40 to 80 years\n* Clinical symptoms consistent with chronic knee pain\n* Radiographically confirmed knee osteoarthritis of Kellgren-Lawrence grade II-IV or persistent knee pain following total knee arthroplasty\n* Insufficient pain relief after standard conservative treatment (e.g., pharmacological therapy, physical therapy, or injections)\n* Ability to understand the study procedures and provide written informed consent \\_ Willingness and ability to comply with the study procedures and follow-up schedule\n\nExclusion Criteria:\n\n* Active local or systemic infection\n* Known coagulation disorders or ongoing anticoagulation that cannot be safely interrupted\n* Significant peripheral arterial disease affecting the lower limbs\n* Known allergy or contraindication to iodinated contrast agents\n* Severe renal impairment\n* History of fibromyalgia or other generalized chronic pain syndromes that may confound pain assessment\n* Pregnancy or breastfeeding","80 Years",{"count":221,"type":20},20,[58],"This clinical study investigates a minimally invasive treatment called percutaneous transcatheter embolization of knee arteries for patients with chronic knee pain caused by advanced knee osteoarthritis or persistent pain after total knee replacement. Osteoarthritis of the knee is a common degenerative condition that can lead to long-term pain, reduced mobility, and decreased quality of life, and some patients do not achieve sufficient relief with standard treatments.\n\nThe study is based on the hypothesis that targeted embolization of small arteries supplying the inflamed tissues of the knee can safely reduce abnormal blood flow associated with inflammation, leading to pain relief and improved knee function. During the procedure, a thin catheter is guided through the blood vessels to the affected area of the knee, where a temporary embolic agent is administered to reduce pathological blood supply.\n\nThe aim of the study is to evaluate the safety and effectiveness of this procedure by assessing changes in pain intensity, knee function, and quality of life over a follow-up period of up to 24 months. The results of this study may help determine whether this minimally invasive approach can offer a new treatment option for patients who have limited alternatives for managing chronic knee pain",[225,226,26],"Osteoarthritic Knee Pain","Osteo Arthritis of the Knee",[228,62,229],"genicular artery embolisation","MSK embolisation","2026-02-02",{"date":232,"type":35},"2026-02-04",{"date":230,"type":35},{"date":235,"type":20},"2029-12-01",{"name":237,"class":42},"Masarykova Nemocnice v Usti nad Labem, Krajska Zdravotni a.s.",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":52,"sex":16,"minAge":54,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":4},"100591196","the-bone-brain-crosstalk-mechanism-of-subchondral-bone-nociceptive-sensitization-activating-spp1-positive-microglia-in-the-vlpag-region-elucidates-the-theoretical-connotation-of-treating-knee-osteoarthritis-based-on-kidney-differentiation-100591196","NCT06977282","The 'Bone-Brain' Crosstalk Mechanism of Subchondral Bone Nociceptive Sensitization Activating SPP1-Positive Microglia in the vlPAG Region Elucidates the Theoretical Connotation of Treating Knee Osteoarthritis Based on Kidney Differentiation","Inclusion Criteria:\n\n* Clinical diagnosis of KOA\n* Age between 60-70 years.\n* Kellgren-Lawrence grade IV on anteroposterior and lateral knee X-rays.\n* Scheduled for total knee arthroplasty.\n* Voluntarily signs informed consent.\n\nExclusion Criteria:\n\n* Clinical diagnosis of ankylosing spondylitis, rheumatoid arthritis, gout, or other related conditions.\n* Presence of metabolic bone diseases, acute trauma, malignancies, infections, or other complications severely affecting knee function.\n* Use of drugs affecting bone metabolism (e.g., corticosteroids, zoledronic acid) within the past 6 months.\n* Presence of psychiatric disorders or serious cardiovascular, pulmonary, renal, hepatic, hematologic, or other systemic diseases.\n* Contraindications to MRI.","70 Years",{"count":246,"type":20},120,"The aim of this observational study is to investigate the relationship between pain severity and alterations in bone-derived and brain-derived signaling molecules (including serum neurotransmitters and inflammatory cytokines), as well as structural and functional changes in the ventrolateral periaqueductal gray (vlPAG) region in patients with kidney-deficiency type knee osteoarthritis (KOA). The central question it seeks to address is whether changes in these signaling molecules and vlPAG alterations are associated with the degree of pain.\n\nPatients scheduled to undergo total knee arthroplasty (TKA) due to KOA will be enrolled prior to surgery. Before the operation, they will undergo questionnaire assessments, physical examinations, imaging evaluations, and blood sample collection. The resected tibial plateau tissue obtained during surgery will be used for subsequent laboratory analyses.",[26],"2025-05-16",{"date":251,"type":35},"2025-05-18",{"date":253,"type":20},"2025-06-15",{"date":255,"type":20},"2026-12-30",{"name":257,"class":42},"Jinchao Xu"]